Literature DB >> 31624605

Successful cryoballoon ablation of a focal atrial tachycardia in a patient with situs inversus and dextrocardia.

Ersan Akkaya1, Korkut Sözener1, Johannes Rixe1, Damir Erkapic1.   

Abstract

Cryoballoon ablation of an arrhythmogenic focus alongside a pulmonary vein as an alternative to radiofrequency ablation may be feasible and safe in patients with situs inversus and dextrocardia.
© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  catheter ablation; cryoballoon; dextrocardia; focal atrial tachycardia; situs inversus

Year:  2019        PMID: 31624605      PMCID: PMC6787809          DOI: 10.1002/ccr3.2304

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN: 2050-0904


INTRODUCTION

A 53‐year‐old woman presented with recurrent, drug‐refractory atrial tachycardia. Situs inversus with dextrocardia was diagnosed in childhood. Catheter ablation with a second‐generation cryoballoon guided by an EnSiteTM NavXTM system was performed successfully with termination of the atrial tachycardia, which originated from the carina inferior to the lateral superior pulmonary vein. This favorable outcome suggests that cryoballoon ablation of an arrhythmogenic focus alongside a pulmonary vein may be feasible and safe in patients with situs inversus and dextrocardia. Cryoballoon (CB)‐based isolation of pulmonary veins (PVs) and left atrial substrate modification is increasingly being used in patients with paroxysmal1 and persistent atrial fibrillation.2 In contrast, focal atrial tachycardia typically responds well to radiofrequency (RF) ablation. However, catheter ablation of an arrhythmogenic focus by means of the second‐generation CB (CB‐Adv; Arctic Front Advance™, Medtronic) in a patient with situs inversus and dextrocardia has not been reported to date. Herein, we report the successful ablation of a focal atrial tachycardia (AT) originating from the carina inferior to the lateral superior PV in a patient with complete situs inversus.

CASE REPORT

A 53‐year‐old woman with drug‐refractory AT and a history of situs inversus and dextrocardia presented for catheter ablation. Preinterventional computed tomography imaging confirmed the abnormal anatomy and ruled out possible malformation of the left atrium and PVs (Figure 1). Written informed consent was obtained after all the potential risks of ablation were discussed with the patient.
Figure 1

Chest radiogram demonstrating dextrocardia

Chest radiogram demonstrating dextrocardia Cryoballoon ablation was performed during AT (cyclus length, 423 ms) under conscious sedation. Biplane fluoroscopy with 30° left and 60° right anterior oblique views was used, and diagnostic mapping was conducted with two 6‐Fr decapolar catheters (ViaCath, Biotronik) via the left femoral vein: one catheter in the coronary sinus (CS) and one in the right ventricular apex. The electrical propagation in the CS suggested a left atrial origin of the AT. The tachycardia was incessant and unresponsive to overdrive pacing. A single transseptal puncture via the right femoral vein was performed under the guidance of transesophageal echocardiography (Philips iE33 system, Philips Medical Systems) with an 8.5‐Fr SL‐1 sheath (Abbott) by means of the modified Brockenbrough technique (BRK‐1, Abbott). Selective PV angiography was performed to identify the PV anatomy. Once transseptal access was obtained, heparin boluses were repeatedly administered to maintain the activated clotting time between 300 and 350 seconds. Three‐dimensional mapping was performed with a circular mapping catheter (AdvisorTM FL, Abbott) via a SL‐1 sheath under the guidance of the NavX system (EnSiteTM NavXTM, Abbott). The local activation time map showed a focal propagation from the carina inferior to the lateral superior PV as the origin of the AT (Figure 2).
Figure 2

Local activation time map demonstrating the earliest activation of the atrial tachycardia (black star). LAA, left atrial appendage; LIPV, lateral inferior pulmonary vein; LSPV, lateral superior pulmonary vein; SIPV, septal inferior pulmonary vein; SSPV, septal superior pulmonary vein

Local activation time map demonstrating the earliest activation of the atrial tachycardia (black star). LAA, left atrial appendage; LIPV, lateral inferior pulmonary vein; LSPV, lateral superior pulmonary vein; SIPV, septal inferior pulmonary vein; SSPV, septal superior pulmonary vein Then, the SL‐1 sheath was exchanged over a guide wire in the lateral superior vein with a 12‐Fr steerable sheath (FlexCath AdvanceTM, Medtronic). The latter was constantly flushed with heparinized saline. Through the steerable sheath, a 20‐mm‐diameter Achieve™ inner‐lumen‐mapping catheter (Medtronic) was placed in the lateral superior PV to record baseline signals. The 28‐mm CB‐Adv was advanced over the Achieve catheter, inflated, and positioned at the PV ostium. To assess the exact position of the inflated balloon in relation to the PV, contrast medium diluted with saline 0.9% (1:1 ratio) was injected from the distal lumen of the CB catheter. Selective contrast injection showed no backflow into the atrium and therefore a total vessel occlusion (Figure 3A). The first attempt at cryoablation, for 240 seconds at a maximum temperature of −51°C, led to immediate deceleration and termination of the tachycardia within 30 seconds of the initiation of cryoenergy application (Figure 3B). During cryoenergy application, diaphragm movement was assessed by intermittent fluoroscopy. No PV activity was noticed within the PVs during AT or sinus rhythm. After 30 minutes of waiting, tachycardia was not inducible in the basal state or under pharmacologic stimulation. A bonus freeze was not performed. Total procedure and fluoroscopy times were 105 and 18 minutes, respectively. Pericardial effusion was excluded by echocardiography immediately after ablation. Venous access site closure was achieved by subcutaneous temporary suture closure after removal of the venous sheaths.3 Preserved phrenic nerve function was documented through diaphragmatic tone by X‐ray examination before discharge. During short‐term follow‐up (90 days), stable sinus rhythm was maintained without any complications or arrhythmia recurrences.
Figure 3

A‐B (A), Visualization of the LSPV with selective contrast injection before starting CB ablation. (B), Electrogram showing the termination of the atrial tachycardia (activation pattern beginning from the distal CS, corresponding number 1/2 on the CS catheter) during CB ablation in the LSPV. CB, cryoballoon; CS, coronary sinus; LSPV, lateral superior pulmonary vein

A‐B (A), Visualization of the LSPV with selective contrast injection before starting CB ablation. (B), Electrogram showing the termination of the atrial tachycardia (activation pattern beginning from the distal CS, corresponding number 1/2 on the CS catheter) during CB ablation in the LSPV. CB, cryoballoon; CS, coronary sinus; LSPV, lateral superior pulmonary vein

DISCUSSION

Cryoballoon ablation is the preferred method for isolation of PVs, especially in patients with ATs originating inside the PVs. In addition, CB‐based isolation of the left4 and right atrial appendages5 for treatment of focal ATs has been reported previously. Furthermore, CB‐based isolation of PVs has been shown to be a feasible approach in patients with situs inversus.6 However, ours is the first report illustrating successful CB ablation of a focal AT originating from the carina inferior to the lateral superior PV in a patient with both situs inversus and dextrocardia. The brief deceleration and immediate termination of the tachycardia as well as the three‐dimensional mapping characteristics were consistent with the automatic nature of the focal AT in this patient. Radiofrequency ablation of ATs shows high success rates and acceptable long‐term outcomes when compared with the CB technique, as reported by Wei et al7 They compared the focal ablation and unilateral PV isolation using RF energy with the CB‐based ablation of ATs originating inside PVs. Nevertheless, the small number of patients (60 RF and 23 CB patients) is a limitation of this trial. Furthermore, there is no evidence for patients with anatomical variations like a situs inversus. However, a recent study found that the low‐voltage area was larger after CB ablation than after RF ablation, and the unexcitable tissue along ablation lines was wider after CB ablation than after RF ablation.8 Additionally, the CB technique reportedly results in larger lesions and fewer lesion gaps in the anterior‐superior segments of the lateral PVs compared with the RF technique.9 In this context, the involvement of greater areas in the ablation maybe important in the case of ATs originating alongside the PVs like in the present report. Furthermore, a large register study showed that the complication rates with CB ablation are lower than those with point‐per‐point RF ablation.10 The ability to perform ablation with the CB as a “single‐shot” device without the needing of more than one transseptal puncture in patients with an unusual left atrial anatomy is an additional argument for performing this ablation procedure empirically in CB technique. The possibility of mapping by means of a three‐dimensional mapping system combining ablation via CB technique can be crucial especially in patients with difficult handling and maneuvering of the sheaths and catheters inside the left atrium due to situs inversus and dextrocardia. The RF as well as the CB technique seems to be an acceptable method for ablation of focal ATs inside or alongside the PVs. Nevertheless, the choice between both approaches depends on the operators' preference and experience. In the authors' opinion, the results reported herein suggest that the CB technique may be an efficient and safe alternative for point‐per‐point ablation of refractory focal ATs inside and between the PVs, especially in patients with situs inversus. More data and experience are necessary to evaluate the role and safety of the CB technique combined with a three‐dimensional mapping system, but equally difficult due to limited number of patients with this anatomical peculiarity.

CONFLICTS OF INTEREST

All authors declare no conflict of interest related to this study.

AUTHOR CONTRIBUTIONS

EA: conceived the data, analyzed the data, drafted the manuscript, and approved the manuscript; KS: critically revised the article and approved the manuscript; JR: contributed to imaging; DE: conceived the data and critically revised the article.
  10 in total

1.  Possible role for cryoballoon ablation of right atrial appendage tachycardia when conventional ablation fails.

Authors:  Basri Amasyali; Ayhan Kilic
Journal:  Tex Heart Inst J       Date:  2015-06-01

2.  Long-term outcome of cryoballoon ablation versus radiofrequency ablation for focal atrial tachycardias originating from the pulmonary veins.

Authors:  Hui-Qiang Wei; Xiao-Gang Guo; Gong-Bu Zhou; Qi Sun; Xu Liu; Bin Luo; Jian-Du Yang; Shu Zhang; Jian Ma
Journal:  J Interv Card Electrophysiol       Date:  2019-01-08       Impact factor: 1.900

3.  Safety and feasibility of percutaneous skin closure using purse-string suture compared with compression bandage after pulmonary vein isolation.

Authors:  Ersan Akkaya; Alexander Berkowitsch; Sergej Zaltsberg; Nikolas Deubner; Harald Greiss; Andreas Hain; Christian W Hamm; Johannes Sperzel; Thomas Neumann; Malte Kuniss
Journal:  J Cardiovasc Electrophysiol       Date:  2017-08-30

Review 4.  Novel usage of the cryoballoon catheter to achieve large area atrial substrate modification in persistent and long-standing persistent atrial fibrillation.

Authors:  Wilber W Su; Muhanad Alzubaidi; Roger Tseng; Nicholas Jebaily; Yenn-Jiang Lin; Paul J Wang
Journal:  J Interv Card Electrophysiol       Date:  2016-03-03       Impact factor: 1.900

5.  Circumferential pulmonary vein isolation with the cryoballoon technique results from a prospective 3-center study.

Authors:  Thomas Neumann; Jürgen Vogt; Burghard Schumacher; Anja Dorszewski; Malte Kuniss; Hans Neuser; Klaus Kurzidim; Alexander Berkowitsch; Marcus Koller; Johannes Heintze; Ursula Scholz; Ulrike Wetzel; Michael A E Schneider; Dieter Horstkotte; Christian W Hamm; Heinz-Friedrich Pitschner
Journal:  J Am Coll Cardiol       Date:  2008-07-22       Impact factor: 24.094

6.  Complications of pulmonary vein isolation in atrial fibrillation: predictors and comparison between four different ablation techniques: Results from the MIddelheim PVI-registry.

Authors:  Yves De Greef; Edwin Ströker; Bruno Schwagten; Kaspars Kupics; Jeroen De Cocker; Gian-Battista Chierchia; Carlo de Asmundis; Dirk Stockman; Ian Buysschaert
Journal:  Europace       Date:  2018-08-01       Impact factor: 5.214

7.  Mechanistic Insights Into Durable Pulmonary Vein Isolation Achieved by Second-Generation Cryoballoon Ablation.

Authors:  Yasuo Okumura; Ichiro Watanabe; Kazuki Iso; Keiko Takahashi; Koichi Nagashima; Kazumasa Sonoda; Hiroaki Mano; Naoko Yamaguchi; Rikitake Kogawa; Ryuta Watanabe; Masaru Arai; Kimie Ohkubo; Sayaka Kurokawa; Toshiko Nakai; Atsushi Hirayama
Journal:  J Atr Fibrillation       Date:  2017-04-30

8.  Successful cryoballoon pulmonary vein isolation in a patient with situs inversus and dextrocardia.

Authors:  Yasuhiro Yoshiga; Akihiko Shimizu; Takeshi Ueyama; Makoto Ono; Tomoko Fumimoto; Hironori Ishiguchi; Masafumi Yano
Journal:  J Arrhythm       Date:  2016-04-23

9.  The lesion characteristics assessed by LGE-MRI after the cryoballoon ablation and conventional radiofrequency ablation.

Authors:  Jun Kurose; Kunihiko Kiuchi; Koji Fukuzawa; Shumpei Mori; Hirotoshi Ichibori; Hiroki Konishi; Yayoi Taniguchi; Kiyohiro Hyogo; Hiroshi Imada; Hideya Suehiro; Yu-Ichi Nagamatsu; Tomomi Akita; Makoto Takemoto; Ken-Ichi Hirata; Shinsuke Shimoyama; Yoshiaki Watanabe; Tatsuya Nishii; Noriyuki Negi; Katsusuke Kyotani
Journal:  J Arrhythm       Date:  2018-01-13

10.  Entrapment of focal atrial tachycardia using cryoballoon ablation; Sinus rhythm in the left atrium and ongoing atrial tachycardia in the left atrial appendage.

Authors:  Hikmet Yorgun; Uğur Canpolat; Banu Evranos; Kudret Aytemir
Journal:  Indian Pacing Electrophysiol J       Date:  2017-10-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.